These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16166443)

  • 1. Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
    Kaufmann SH; Karp JE; Letendre L; Kottke TJ; Safgren S; Greer J; Gojo I; Atherton P; Svingen PA; Loegering DA; Litzow MR; Sloan JA; Reid JM; Ames MM; Adjei AA; Erlichman C
    Clin Cancer Res; 2005 Sep; 11(18):6641-9. PubMed ID: 16166443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
    Cooper BW; Veal GJ; Radivoyevitch T; Tilby MJ; Meyerson HJ; Lazarus HM; Koc ON; Creger RJ; Pearson G; Nowell GM; Gosky D; Ingalls ST; Hoppel CL; Gerson SL
    Clin Cancer Res; 2004 Oct; 10(20):6830-9. PubMed ID: 15501959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
    Rowinsky EK; Kaufmann SH; Baker SD; Miller CB; Sartorius SE; Bowling MK; Chen TL; Donehower RC; Gore SD
    Clin Cancer Res; 1996 Dec; 2(12):1921-30. PubMed ID: 9816150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.
    Litzow MR; Peethambaram PP; Safgren SL; Keeney GL; Ansell SM; Dispenzieri A; Elliott MA; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Micallef IN; Porrata LF; Lingle WL; Hartmann LC; Frost MH; Barrette BA; Long HJ; Suman VJ; Reid JM; Ames MM; Kaufmann SH
    Bone Marrow Transplant; 2010 Mar; 45(3):490-7. PubMed ID: 19648970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
    Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH
    Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
    Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
    Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
    Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study.
    Crump M; Lipton J; Hedley D; Sutton D; Shepherd F; Minden M; Stewart K; Beare S; Eisenhauer E
    Leukemia; 1999 Mar; 13(3):343-7. PubMed ID: 10086724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
    Prince HM; Rischin D; Quinn M; Allen D; Planner R; Neesham D; Gates P; Davison J
    Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
    Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.
    Rose PG; Smrekar M; Haba P; Visser C; Beeler JF
    Gynecol Oncol; 2005 Dec; 99(3):714-9. PubMed ID: 16112177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide.
    Miller AA; Niell HB
    Lung Cancer; 2001; 33(2-3):241-8. PubMed ID: 11551419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.
    Morgan RJ; Synold T; Mamelak A; Lim D; Al-Kadhimi Z; Twardowski P; Leong L; Chow W; Margolin K; Shibata S; Somlo G; Yen Y; Frankel P; Doroshow JH
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):927-33. PubMed ID: 20107803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.
    Pratz KW; Rudek MA; Gojo I; Litzow MR; McDevitt MA; Ji J; Karnitz LM; Herman JG; Kinders RJ; Smith BD; Gore SD; Carraway HE; Showel MM; Gladstone DE; Levis MJ; Tsai HL; Rosner G; Chen A; Kaufmann SH; Karp JE
    Clin Cancer Res; 2017 Feb; 23(4):899-907. PubMed ID: 27551000
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
    Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
    J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.
    Bos AM; De Vos FY; de Vries EG; Beijnen JH; Rosing H; Mourits MJ; van der Zee AG; Gietema JA; Willemse PH
    Eur J Cancer; 2005 Mar; 41(4):539-48. PubMed ID: 15737558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial.
    Kurata T; Kashii T; Takeda K; Seki N; Tsuboi M; Kobayashi M; Satoh T; Nakagawa K; Fukuoka M
    J Thorac Oncol; 2009 May; 4(5):644-8. PubMed ID: 19325498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.
    Kancherla RR; Nair JS; Ahmed T; Durrani H; Seiter K; Mannancheril A; Tse-Dinh YC
    Cancer; 2001 Feb; 91(3):463-71. PubMed ID: 11169927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.